Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EPRX Eupraxia Pharmaceuticals	$3.86 -0.5%	$3.74	$2.20 ▼ $4.48	$138.79M	0.65	13,216 shs	4,408 shs
KYTX Kyverna Therapeutics	$3.22 -6.9%	$2.36	$1.78 ▼ $11.40	$139.17M	2.52	397,663 shs	288,515 shs
MDCX Medicus Pharma	$2.60 -6.8%	$4.34	$1.80 ▼ $8.94	$35.29M	N/A	136,814 shs	133,381 shs
NKTX Nkarta	$1.86 -2.6%	$1.85	$1.31 ▼ $8.23	$131.98M	0.72	1.06 million shs	458,497 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EPRX Eupraxia Pharmaceuticals	-0.52%	-1.91%	-2.03%	-6.99%	+42.44%
KYTX Kyverna Therapeutics	-6.94%	-5.01%	+49.77%	+28.80%	-76.56%
MDCX Medicus Pharma	-6.81%	-5.80%	-58.86%	-20.97%	+259,999,900.00%
NKTX Nkarta	-2.62%	-2.11%	-0.53%	+12.05%	-70.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EPRX Eupraxia Pharmaceuticals	2.2871 of 5 stars	3.7	1.0	2.7	0.0	0.6
KYTX Kyverna Therapeutics	2.4776 of 5 stars	3.6	3.0	3.0	1.7	0.0
MDCX Medicus Pharma	1.7621 of 5 stars	3.8	0.0	2.2	0.8	0.0
NKTX Nkarta	3.6249 of 5 stars	4.6	3.0	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EPRX Eupraxia Pharmaceuticals	3.33	Buy	$10.50	172.02% Upside
KYTX Kyverna Therapeutics	3.14	Buy	$18.50	474.53% Upside
MDCX Medicus Pharma	3.50	Strong Buy	$23.50	803.85% Upside
NKTX Nkarta	3.13	Buy	$14.33	670.61% Upside

Current Analyst Ratings Breakdown

Latest MDCX, KYTX, NKTX, and EPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
6/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
5/29/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
5/27/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $5.00
5/22/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00
5/15/2025	NKTX Nkarta	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
5/15/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
5/12/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$14.00 ➝ $27.00
5/8/2025	MDCX Medicus Pharma	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $20.00
4/28/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/21/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	$0.03 per share	N/A
KYTX Kyverna Therapeutics	$7.03M	19.80	N/A	N/A	N/A	∞
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.56 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EPRX Eupraxia Pharmaceuticals	-$28.22M	-$0.76	N/A	N/A	N/A	N/A	-219.64%	-96.00%	8/6/2025 (Estimated)
KYTX Kyverna Therapeutics	-$60.37M	-$3.38	N/A	N/A	N/A	N/A	-51.12%	-37.91%	8/11/2025 (Estimated)
MDCX Medicus Pharma	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	6/27/2025 (Estimated)
NKTX Nkarta	-$117.50M	-$1.51	N/A	N/A	N/A	N/A	-27.13%	-21.67%	8/12/2025 (Estimated)

Latest MDCX, KYTX, NKTX, and EPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	NKTX Nkarta	-$0.44	-$0.43	+$0.01	-$0.43	N/A	N/A
5/13/2025	Q1 2025	KYTX Kyverna Therapeutics	-$1.21	-$1.03	+$0.18	-$1.03	N/A	N/A
5/12/2025	Q1 2025	MDCX Medicus Pharma	-$0.23	-$0.42	-$0.19	-$0.42	N/A	N/A
5/6/2025	Q1 2025	EPRX Eupraxia Pharmaceuticals	-$0.19	-$0.21	-$0.02	-$0.21	N/A	N/A
3/28/2025	Q4 2024	MDCX Medicus Pharma	-$0.32	-$0.18	+$0.14	-$0.18	N/A	N/A
3/27/2025	Q4 2024	KYTX Kyverna Therapeutics	-$0.87	-$0.88	-$0.01	-$0.88	N/A	N/A
3/26/2025	Q4 2024	NKTX Nkarta	-$0.41	-$0.35	+$0.06	-$0.35	N/A	N/A
3/20/2025	Q4 2024	EPRX Eupraxia Pharmaceuticals	-$0.20	-$0.21	-$0.01	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EPRX Eupraxia Pharmaceuticals	N/A	4.17	4.17
KYTX Kyverna Therapeutics	N/A	10.50	10.50
MDCX Medicus Pharma	N/A	N/A	N/A
NKTX Nkarta	N/A	12.91	12.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EPRX Eupraxia Pharmaceuticals	N/A
KYTX Kyverna Therapeutics	18.08%
MDCX Medicus Pharma	N/A
NKTX Nkarta	80.54%

Insider Ownership

Company	Insider Ownership
EPRX Eupraxia Pharmaceuticals	N/A
KYTX Kyverna Therapeutics	22.00%
MDCX Medicus Pharma	N/A
NKTX Nkarta	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EPRX Eupraxia Pharmaceuticals	29	35.96 million	N/A	N/A
KYTX Kyverna Therapeutics	96	43.22 million	N/A	Optionable
MDCX Medicus Pharma	N/A	13.57 million	N/A	N/A
NKTX Nkarta	140	70.96 million	64.43 million	Optionable

MDCX, KYTX, NKTX, and EPRX Headlines

Recent News About These Companies

Mizuho Lowers Nkarta (NASDAQ:NKTX) Price Target to $14.00

June 12 at 1:55 AM | americanbankingnews.com

Nkarta (NASDAQ:NKTX) Given New $14.00 Price Target at Mizuho

June 10, 2025 | marketbeat.com

Nkarta, Inc. (NASDAQ:NKTX) Receives Consensus Recommendation of "Buy" from Analysts

June 10, 2025 | marketbeat.com

Bank of America Corp DE Grows Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX)

June 8, 2025 | marketbeat.com

Nkarta CMO David Shook Steps Down, Shawn Rose To Succeed

June 8, 2025 | nasdaq.com

Nkarta, Inc.: Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

June 6, 2025 | finanznachrichten.de

Nkarta, Inc. Appoints Dr. Shawn Rose as Chief Medical Officer and Head of R&D

June 6, 2025 | quiverquant.com

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

June 6, 2025 | globenewswire.com

Millennium Management LLC Boosts Position in Nkarta, Inc. (NASDAQ:NKTX)

June 4, 2025 | marketbeat.com

Jefferies Financial Group Inc. Boosts Stock Position in Nkarta, Inc. (NASDAQ:NKTX)

May 28, 2025 | marketbeat.com

BNP Paribas Financial Markets Invests $507,000 in Nkarta, Inc. (NASDAQ:NKTX)

May 26, 2025 | marketbeat.com

AWM Investment Company Inc. Makes New $996,000 Investment in Nkarta, Inc. (NASDAQ:NKTX)

May 23, 2025 | marketbeat.com

Equities Analysts Issue Forecasts for Nkarta FY2025 Earnings

May 21, 2025 | marketbeat.com

Tang Capital Management LLC Acquires 1,643,719 Shares of Nkarta, Inc. (NASDAQ:NKTX)

May 20, 2025 | marketbeat.com

Leerink Partnrs Analysts Lower Earnings Estimates for Nkarta

May 20, 2025 | marketbeat.com

William Blair Comments on Nkarta's Q2 Earnings (NASDAQ:NKTX)

May 20, 2025 | marketbeat.com

Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade

May 19, 2025 | zacks.com

Dimensional Fund Advisors LP Has $1.42 Million Stock Position in Nkarta, Inc. (NASDAQ:NKTX)

May 18, 2025 | marketbeat.com

Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of "Buy" by Analysts

May 18, 2025 | marketbeat.com

Bridgeway Capital Management LLC Has $50,000 Position in Nkarta, Inc. (NASDAQ:NKTX)

May 16, 2025 | marketbeat.com

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

May 15, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDCX, KYTX, NKTX, and EPRX Company Descriptions

Eupraxia Pharmaceuticals NASDAQ:EPRX

$3.86 -0.02 (-0.52%)

As of 06/13/2025 03:59 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Kyverna Therapeutics NASDAQ:KYTX

$3.22 -0.24 (-6.94%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$3.34 +0.12 (+3.57%)

As of 06/13/2025 07:41 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Medicus Pharma NASDAQ:MDCX

$2.60 -0.19 (-6.81%)

As of 06/13/2025 04:00 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

Nkarta NASDAQ:NKTX

$1.86 -0.05 (-2.62%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.88 +0.01 (+0.81%)

As of 06/13/2025 07:58 PM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time